Metformin safe for psoriatic patients with diabetes

14 Jul 2019

Clinicians need not worry about prescribing metformin for psoriatic patients with type 2 diabetes mellitus (T2DM), as results of a recent study show no safety concerns.

To examine the real-world safety of metformin in psoriatic patients with T2DM, the investigators conducted a cohort study using the National Health Insurance Research Database. All patients were divided into the metformin and the nonmetformin group based on their antidiabetic prescriptions.

The outcomes included all-cause mortality, severe psoriasis, hospitalization due to psoriasis and any cause for readmission.

A total of 5,520 and 3,062 patients were enrolled in the metformin and nonmetformin groups, respectively. No significant between-group difference was observed in terms of the risk of all-cause mortality (hazard ratio [HR], 1.08, 95 percent CI, 0.90–1.30), severe psoriasis (HR, 0.95, 0.80–1.09), psoriasis-related admission (HR, 1.32, 0.90–1.93) and any-cause readmission (HR, 0.99, 0.90–1.11).

In the dose-response analysis, there was no significant increase in the risk of severe psoriasis and psoriasis-related admission, even with prescribing >80 defined daily doses or >1,000 mg daily dose of metformin (p-trend>0.05).

A previous study involving psoriatic patients with metabolic syndrome (MS) showed that metformin is effective in improving psoriasis and parameters of MS and can be used for the benefit of this patient population. [Indian J Endocrinol Metab 2017;21:581-587]

In a cross-sectional study performed on 48 Vietnamese patients with psoriasis, results indicated that combined therapy with metformin and methotrexate significantly improved the quality of life for patients with psoriasis. [Open Access Maced J Med Sci 2019;7:302-303]

Editor's Recommendations
Most Read Articles